Treatment of systemic lupus erythematosus with cyclophosphamide

被引:0
|
作者
Backhaus, M
Hiepe, F
机构
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 1997年 / 56卷 / 04期
关键词
systemic lupus erythematosus; lupus nephritis; cyclophosphamide; methylprednisolone;
D O I
10.1007/s003930050033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cyclophosphamide is a potent immunosuppressive drug which is widely used to treat renal and central nervous system manifestation of Systemic Lupus Erythematosus (SLE). It is employed especially to prevent renal failure in lupus nephritis. Within the last decade intravenous cyclophosphamide bolus therapy has become the standard therapy in severe SLE due to its tendency towards a higher efficacy and fewer side effects as compared to oral application. Studies on the slightly more cost-effective oral cyclophosphamide bolus therapy have recently been published, however, there are no data on long-term results yet. Here, we review the effects and side effects of cyclophosphamide as well as recent clinical studies on cyclophosphamide bolus therapy in SLE. Because of the possible side effects, especially the high risk of malignancies, which sharply increases at a cumulative dose of approximately 60 g, cyclophosphamide should be used cautiously. Cyclophosphamide bolus therapy should only be performed in hospitals with special experience.
引用
收藏
页码:178 / 189
页数:12
相关论文
共 50 条
  • [21] Mastitis refractory to cyclophosphamide in systemic lupus erythematosus
    Castro, GRW
    Appenzeller, S
    Soledade, C
    Bértolo, MB
    Costallat, LTL
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (06) : 786 - 786
  • [22] Cyclophosphamide: new approaches for systemic lupus erythematosus
    Petri, M
    LUPUS, 2004, 13 (05) : 366 - 371
  • [23] CYCLOPHOSPHAMIDE IN HEMATOLOGICAL SYSTEMIC LUPUS-ERYTHEMATOSUS
    MILLIGAN, DW
    DELAMORE, IW
    BRITISH MEDICAL JOURNAL, 1982, 285 (6351): : 1352 - 1352
  • [24] Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus
    Wolf, Victoria L.
    Taylor, Erin B.
    Ryan, Michael J.
    PHYSIOLOGICAL REPORTS, 2019, 7 (10):
  • [25] ROLE OF INTRAVENOUS CYCLOPHOSPHAMIDE IN THE TREATMENT OF SEVERE NEUROPSYCHIATRIC SYSTEMIC LUPUS-ERYTHEMATOSUS
    NEUWELT, CM
    LACKS, S
    KAYE, BR
    ELLMAN, JB
    BORENSTEIN, DG
    AMERICAN JOURNAL OF MEDICINE, 1995, 98 (01): : 32 - 41
  • [26] Combination of rituximab and cyclophosphamide for the treatment of chilhood onset systemic lupus erythematosus.
    Barillas-Arias, Lilliana
    Adams, Alexa B.
    Angeles, Sheila T.
    MacDermott, Emma J.
    Barinstein, Laura
    Lehman, Thomas J. A.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S689 - S690
  • [27] Efficacy of leflunomide in the treatment of systemic lupus erythematosus refractory to cyclophosphamide - A pilot study
    Tam, L
    Li, EK
    Wong, C
    Lam, C
    Szeto, C
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 243 - 243
  • [28] Premature ovarian failure in systemic lupus erythematosus patients: is it related to cyclophosphamide treatment?
    Rasha M. Ghaleb
    Khaled A. Fahmy
    Egyptian Rheumatology and Rehabilitation, 2019, 46 (2) : 85 - 91
  • [29] CLINICAL EVALUATION OF CYCLOPHOSPHAMIDE PREDNISONE ASSOCIATION IN TREATMENT OF SYSTEMIC LUPUS-ERYTHEMATOSUS
    CHAHADE, WH
    JOSEF, H
    FEDERICO, WA
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1975, 4 : 917 - 917
  • [30] Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide
    McDermott, EM
    Powell, RJ
    ANNALS OF THE RHEUMATIC DISEASES, 1996, 55 (04) : 224 - 229